Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response
Elevated expression of RNA binding protein HNRNPC has been reported in cancer cells, while the essentialness and functions of HNRNPC in tumors were not clear. We showed that repression of HNRNPC in the breast cancer cells MCF7 and T47D inhibited cell proliferation and tumor growth. Our computational inference of the key pathways and extensive experimental investigations revealed that the cascade of interferon responses mediated by RIG-I was responsible for such tumor-inhibitory effect. Interestingly, repression of HNRNPC resulted in accumulation of endogenous double-stranded RNA (dsRNA), the binding ligand of RIG-I. These up-regulated dsRNA species were highly enriched by Alu sequences and mostly originated from pre-mRNA introns that harbor the known HNRNPC binding sites. Such source of dsRNA is different than the recently well-characterized endogenous retroviruses that encode dsRNA. In summary, essentialness of HNRNPC in the breast cancer cells was attributed to its function in controlling the endogenous dsRNA and the down-stream interferon response. This is a novel extension from the previous understandings about HNRNPC in binding with introns and regulating RNA splicing.
Publication date: Available online 20 November 2019Source: European Journal of Surgical OncologyAuthor(s): Isabel T. Rubio, Michalis Kontos, M.J. Vrancken-Peeters, Roman Rouzier, Anita Rohini, Viviana Galimberti, Niels Kroman, Carmela Caballero, Shinji Ohno, BIG Task Force Surgical Trials
Conclusions: Although liquid biopsy remains challenging, a combination of SPAG6, NKX2-6, ITIH5 and PER1 (SNiPER) provides a promising tool for blood-based breast cancer detection. PMID: 31741713 [PubMed]
ConclusionsTumor-nipple enhancement and tumor-nipple distance on MRI could predict NAC involvement in breast cancer. When enhancement was evaluated on both early and delayed phase images with a combined tumor-nipple distance of ≤1 cm, the prediction of NAC involvement showed the best performance.
Conditions: Breast Cancer; DCIS Intervention: Device: LifeExtend-AI Sponsor: Indiana University Not yet recruiting
Condition: Breast Cancer Female Interventions: Drug: Metformin Hydrochloride 850 mg Tablets; Drug: AC-T chemotherapy regimen Sponsors: Damanhour University; Alexandria University Recruiting
Conditions: Breast Cancer; Morbid Obesity; Bariatric Surgery Candidate Intervention: Procedure: Bariatric surgery Sponsor: The Cleveland Clinic Not yet recruiting
Conditions: Breast Carcinoma; Mammoplasty Patient Interventions: Other: Diary; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
ConclusionFor women both with and without diagnosed breast cancer, cost was a major concern in seeking medical services. Affordability and access to breast cancer screening and treatment need to be improved. Providing more comprehensive insurance coverage is a key solution.
Radionecrosis has emerged as a side effect of SRS in patients with breast cancer brain metastases. Here, we look at its challenges and treatments.Medscape Oncology
Conclusion: Addition of emodin attenuated tamoxifen's treatment effect via cyclin D1 and pERK up-regulation in ER-positive breast cancer cell lines. PMID: 31742207 [PubMed]